ATE468856T1 - Verfahren zur erhöhung der analgetischen wirkung und zur verringerung der unerwünschten exitatorischen wirkungen von bimodalisch wirksamen opioidagonisten durch die hemmung von gm1-gangliosid - Google Patents

Verfahren zur erhöhung der analgetischen wirkung und zur verringerung der unerwünschten exitatorischen wirkungen von bimodalisch wirksamen opioidagonisten durch die hemmung von gm1-gangliosid

Info

Publication number: ATE468856T1
Authority: AT; Austria
Prior art keywords: ganglioside; inhibiting; present; exitative; bimodalic
Prior art date: 2001-03-23

Application number

AT02733865T

Other languages

English (en)

Inventor

Stanley Crain

Ke-Fei Shen

Original Assignee

Einstein Coll Med

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-23

Filing date

2002-03-19

Publication date

2010-06-15

2002-03-19 Application filed by Einstein Coll Med filed Critical Einstein Coll Med

2010-06-15 Application granted granted Critical

2010-06-15 Publication of ATE468856T1 publication Critical patent/ATE468856T1/de

Links

238000000034 method Methods 0.000 title abstract 5
230000000202 analgesic effect Effects 0.000 title abstract 2
QPJBWNIQKHGLAU-IQZHVAEDSA-N ganglioside GM1 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 QPJBWNIQKHGLAU-IQZHVAEDSA-N 0.000 title abstract 2
230000002401 inhibitory effect Effects 0.000 title abstract 2
229940127450 Opioid Agonists Drugs 0.000 title 1
230000000694 effects Effects 0.000 title 1
208000002193 Pain Diseases 0.000 abstract 2
239000003402 opiate agonist Substances 0.000 abstract 2
208000000094 Chronic Pain Diseases 0.000 abstract 1
206010012335 Dependence Diseases 0.000 abstract 1
239000000730 antalgic agent Substances 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1
210000000929 nociceptor Anatomy 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Emergency Medicine (AREA)
Neurosurgery (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurology (AREA)
Inorganic Chemistry (AREA)
Anesthesiology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Cosmetics (AREA)

AT02733865T 2001-03-23 2002-03-19 Verfahren zur erhöhung der analgetischen wirkung und zur verringerung der unerwünschten exitatorischen wirkungen von bimodalisch wirksamen opioidagonisten durch die hemmung von gm1-gangliosid ATE468856T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US27852901P	2001-03-23	2001-03-23
PCT/US2002/008472 WO2002076388A2 (en)	2001-03-23	2002-03-19	Methods for increasing analgesic potency and attenuating adverse excitatory effects of bimodally-acting opioid agonists by inhibiting gm1-ganglioside

Publications (1)

Publication Number	Publication Date
ATE468856T1 true ATE468856T1 (de)	2010-06-15

Family

ID=23065325

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02733865T ATE468856T1 (de)	2001-03-23	2002-03-19	Verfahren zur erhöhung der analgetischen wirkung und zur verringerung der unerwünschten exitatorischen wirkungen von bimodalisch wirksamen opioidagonisten durch die hemmung von gm1-gangliosid

Country Status (9)

Country	Link
US (3)	US20020137761A1 (de)
EP (1)	EP1370275B1 (de)
JP (1)	JP2005500258A (de)
AT (1)	ATE468856T1 (de)
AU (1)	AU2002305066B8 (de)
CA (1)	CA2441889A1 (de)
DE (1)	DE60236496D1 (de)
NZ (1)	NZ528771A (de)
WO (1)	WO2002076388A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5968547A (en)	1997-02-24	1999-10-19	Euro-Celtique, S.A.	Method of providing sustained analgesia with buprenorphine
DE10141650C1 (de)	2001-08-24	2002-11-28	Lohmann Therapie Syst Lts	Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
AU2002336653A1 (en) *	2001-10-24	2003-05-06	Luciano Mastronardi	Management of postoperative pain
WO2004054554A1 (en) *	2002-12-13	2004-07-01	Euro-Celtique S.A.	Transdermal buprenorphine to treat pain in sickle cell crisis
US20040202717A1 (en)	2003-04-08	2004-10-14	Mehta Atul M.	Abuse-resistant oral dosage forms and method of use thereof
US20070276024A1 (en) *	2003-10-09	2007-11-29	Inverseon , Inc.	Methods for Treating Diseases and Conditions with Inverse Agonists and for Screening for Agents Acting as Inverse Agonists
EP1677778A2 (de) *	2003-10-09	2006-07-12	Inverseon, Inc.	Verfahren zur behandlung von atemwegserkrnakungen mit betaadrenergen inversen agonisten
US20050245557A1 (en) *	2003-10-15	2005-11-03	Pain Therapeutics, Inc.	Methods and materials useful for the treatment of arthritic conditions, inflammation associated with a chronic condition or chronic pain
US20060009478A1 (en) *	2003-10-15	2006-01-12	Nadav Friedmann	Methods for the treatment of back pain
US7528175B2 (en) *	2004-10-08	2009-05-05	Inverseon, Inc.	Method of treating airway diseases with beta-adrenergic inverse agonists
US20070087977A1 (en) *	2004-11-16	2007-04-19	Wendye Robbins	Methods and compositions for treating pain
CA2587406A1 (en) *	2004-11-16	2006-05-26	Limerick Neurosciences, Inc.	Methods and compositions for treating pain
JP5276982B2 (ja)	2005-08-26	2013-08-28	ボードオブトラスティーズオブザレランドスタンフォードジュニアユニバーシティ	オキシトシンの投与による頭痛の処置のための方法
WO2008054475A2 (en) *	2006-03-13	2008-05-08	The Trustees Of Columbia University In The City Of New York	Neuraminidase inhibitors and uses thereof
WO2008060381A2 (en) *	2006-11-01	2008-05-22	Albert Einstein College Of Medicine Of Yeshiva University	Method for treating pain or opioid dependence using a specific type of non-opioid agent in combination with a selective excitatory-opioid-receptor inactivator
US20100086543A1 (en) *	2007-04-02	2010-04-08	Saint Louis University	Compositions and methods for treating conditions associated with ceramide biosynthesis
US20080241121A1 (en) *	2007-04-02	2008-10-02	Daniela Salvemini	Inhibitors of the ceramide metabolic pathway as adjuncts to opiates for pain
TWI473614B (zh)	2008-05-29	2015-02-21	Kyowa Hakko Kirin Co Ltd	Anti-analgesic inhibitors
CN102539764A (zh) *	2010-12-27	2012-07-04	北京库尔科技有限公司	盐酸哌替啶检测试剂盒及其制备方法
CN102539765A (zh) *	2010-12-29	2012-07-04	北京宝瑞源科技孵化有限公司	三唑仑检测试剂盒及其制备方法
CN102721809A (zh) *	2011-03-29	2012-10-10	库尔医疗技术(北京)有限公司	林可霉素检测试剂盒及其制备方法
KR102082529B1 (ko) *	2012-04-17	2020-02-27	퍼듀 퍼머 엘피	오피오이드-유도 유해 약역학 반응을 치료하기 위한 시스템 및 방법
SG11201705591PA (en)	2015-01-07	2017-08-30	Trigemina Inc	Magnesium-containing oxytocin formulations and methods of use
JP7093559B2 (ja)	2016-04-12	2022-06-30	トライジェミナ，インコーポレイテッド	マグネシウム含有オキシトシン製剤および使用の方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9115596D0 (en) *	1991-07-12	1991-09-04	Creighton Andrew M	Pharmaceutical compositions
WO1993013128A1 (en) *	1991-12-30	1993-07-08	Neurex Corporation	Methods of producing analgesia and enhancing opiate analgesia
US6284236B1 (en) *	1995-06-29	2001-09-04	Immunex Corporation	Cytokine that induces apoptosis
US6174878B1 (en) *	1999-08-31	2001-01-16	Alcon Laboratories, Inc.	Topical use of kappa opioid agonists to treat otic pain

2002
- 2002-03-19 DE DE60236496T patent/DE60236496D1/de not_active Expired - Lifetime
- 2002-03-19 JP JP2002574904A patent/JP2005500258A/ja active Pending
- 2002-03-19 AU AU2002305066A patent/AU2002305066B8/en not_active Ceased
- 2002-03-19 WO PCT/US2002/008472 patent/WO2002076388A2/en not_active Ceased
- 2002-03-19 CA CA002441889A patent/CA2441889A1/en not_active Abandoned
- 2002-03-19 NZ NZ528771A patent/NZ528771A/en unknown
- 2002-03-19 US US10/101,806 patent/US20020137761A1/en not_active Abandoned
- 2002-03-19 AT AT02733865T patent/ATE468856T1/de not_active IP Right Cessation
- 2002-03-19 EP EP02733865A patent/EP1370275B1/de not_active Expired - Lifetime
2003
- 2003-06-11 US US10/459,418 patent/US20040087607A1/en not_active Abandoned
2009
- 2009-09-23 US US12/586,518 patent/US20100015147A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20020137761A1 (en)	2002-09-26
US20100015147A1 (en)	2010-01-21
WO2002076388A2 (en)	2002-10-03
NZ528771A (en)	2007-03-30
WO2002076388A3 (en)	2002-12-19
EP1370275B1 (de)	2010-05-26
CA2441889A1 (en)	2002-10-03
EP1370275A4 (de)	2006-06-07
JP2005500258A (ja)	2005-01-06
AU2002305066B2 (en)	2007-12-20
US20040087607A1 (en)	2004-05-06
AU2002305066B8 (en)	2008-04-17
EP1370275A2 (de)	2003-12-17
DE60236496D1 (de)	2010-07-08

Similar Documents

Publication	Publication Date	Title
ATE468856T1 (de)	2010-06-15	Verfahren zur erhöhung der analgetischen wirkung und zur verringerung der unerwünschten exitatorischen wirkungen von bimodalisch wirksamen opioidagonisten durch die hemmung von gm1-gangliosid
ATE214276T1 (de)	2002-03-15	Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit
PL1691892T3 (pl)	2007-07-31	Odporna na fizyczne manipulowanie, współwytłaczana postać dawkowania zawierająca środek aktywny i środek przeciwdziałający oraz sposób wytwarzania tej postaci
IL267381A (en)	2019-08-29	A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
ATE446751T1 (de)	2009-11-15	Verwendung von methylnaltrexon zur behandlung von immunsuppression
DE60038290D1 (de)	2008-04-24	Opioidantagonisthaltige zusammensetzung zur erhöhung der analgetischen wirksamkeit von tramadol und verringerung von ihre nebenwirkungen
RU2005113996A (ru)	2005-10-27	Способы лечения боли введением антагониста фактора роста нервов и опиоидного анальгетика, и содержащие их композиции
WO2004091540A3 (en)	2006-02-02	Methods of treating pain and compositions for use therefor
DE602004012745D1 (de)	2008-05-08	Synergistische zusammensetzung zur behandlung von diabetes mellitus
DE69833971D1 (de)	2006-05-11	Verfahren zur behandlung von alzheimerschen krankheit
BR0207526A (pt)	2004-03-09	Composto, composição farmacêutica, e, métodos para o tratamento da dor, da enxaqueca, depressão, ansiedade, esquizofrenia, doença de parkinson ou derrame cerebral
BRPI0409523A (pt)	2006-04-18	método para o tratamento da dor neuropática, método de identificação de um composto e composição farmacêutica
PT1530469E (pt)	2009-05-19	Forma de dosagem transdérmica que compreende um agente activo, um sal e uma forma de base livre de um antagonista
DE69941949D1 (de)	2010-03-11	topische ZUSAMMENSETZUNGEN enthaltend einen alpha 1-adrenergic blocker ZUR BEHANDLUNG VON SCHMERZHAFTEN ZUSTÄNDEN DER ANALREGION
ATE250932T1 (de)	2003-10-15	Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer
EA200400734A1 (ru)	2004-12-30	Способ и композиция для потенциирования действия опиатного анальгетика
MXPA03007885A (es)	2004-05-24	Norbuprenorfina n-but-3-enilo y metodos de uso.
BR0210377A (pt)	2004-08-10	Compostos de n-formil hidroxil amina
DE60042282D1 (de)	2009-07-09	Neue methoden und verfahren zur behandlung und vermeidung von ileus
IS7517A (is)	2004-10-28	Efnasambönd sem nýtast í meðferð við miltisbrandiog hindra banvænan þátt
BR9508406A (pt)	1997-12-23	Uso de um composto e método para o tratamento e/ou profilaxia em mamíferos
BR0312470A (pt)	2005-04-26	Composto, uso do mesmo, composição farmacêutica, método de tratar e/ou prevenir câncer, e, processo para preparar o composto
DE60236077D1 (de)	2010-06-02	Analgetische zusammensetzung enthaltend ein opioid und einen natriumkanalblocker
ATE473001T1 (de)	2010-07-15	Suchtpraevention in der schmerzbehandlung mit gamma vinyl gaba
BRPI0410026A (pt)	2006-04-25	derivados de 3-amino-croman quinolina

Legal Events

Date	Code	Title	Description
2010-11-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties